Key Highlights

  • IVF reported second-quarter 2026 Revenue of $2,175,485, up 17 percent year over year, with consolidated clinic revenue increasing 18 percent to $2,167,785.
  • Clinic-level adjusted EBITDA before corporate operating and public company expenses was approximately $333,000, up from approximately $164,000 in the first quarter of 2026.
  • Net income was $0.9 million, compared with a net loss of $3.6 million a year earlier, aided by an approximately $2.5 million gain on remeasurement related to the Birmingham clinic acquisition.
  • The company ended the quarter with $3.7 million in cash, up from approximately $2.1 million at the end of 2025, following the June Acquisition of full ownership in its Birmingham, Alabama fertility clinic.

Family Beginnings Acquisition Drives Organic and Inorganic Growth

INVO Fertility, Inc. (NASDAQ:IVF), a Sarasota, Florida-based healthcare fertility company focused on establishing, acquiring, and operating fertility clinics, said its 17 percent revenue increase was driven primarily by the first full-quarter contribution from its Indiana-based Family Beginnings clinic, acquired in February 2026, alongside organic growth initiatives at its Wisconsin Fertility Institute and Georgia clinic. Management said these results reinforce the company's two primary growth avenues of organic growth within its existing clinic base and disciplined acquisitions of established, profitable fertility practices.

Because Family Beginnings' contribution will begin to lap the year-ago comparison in future quarters, the durability of the company's revenue growth rate will increasingly depend on organic performance at existing clinics and the pace of any new acquisitions, rather than the acquisition-driven boost that characterized this period.

Birmingham Clinic Conversion Adds Full Economic Participation

In June 2026, the company acquired the remaining ownership interests in its Birmingham, Alabama fertility clinic, converting the operation from a joint venture into a Wholly Owned Subsidiary and giving INVO full operational control and 100 percent participation in future economics. This transaction generated an approximately $2.5 million non-cash gain on remeasurement that was the primary driver of the quarter's positive net income, a result that would not recur in future periods absent additional similar transactions.

Because this remeasurement gain is a one-time accounting item tied specifically to the Birmingham ownership conversion, investors should distinguish between the quarter's reported net income, which benefited substantially from this non-cash item, and the underlying clinic-level adjusted EBITDA figure that management uses to track the platform's recurring operating performance.

Clinic-Level Profitability Improves as Platform Scales

Clinic-level adjusted EBITDA, which measures Earnings from the company's fertility clinic operations before corporate operating expenses, more than doubled to approximately $333,000 from approximately $164,000 in the first quarter, though total company adjusted EBITDA remained negative at approximately $1.0 million after accounting for corporate and public company costs. Management said it continues to invest in shared operations, human resources, and finance capabilities designed to support a larger clinic network and improve execution as it integrates future acquisitions, with the goal of allowing corporate expenses to be supported across a larger revenue and earnings base over time.

Conclusion

INVO Fertility's improving clinic-level profitability and full ownership of its Birmingham operation support management's strategy of pairing organic growth with disciplined acquisitions of established fertility practices. The pace at which clinic-level adjusted EBITDA continues to scale relative to corporate overhead, along with the company's ability to execute on its stated pipeline of additional acquisition opportunities, will be the key factors determining whether the platform can achieve consolidated profitability in future periods.